GMP IPO Watch
qsif Sector Rotation Long-Short Fund
Direct Plan · Growth Option · qsif SIF
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.54% | +3.54% | 1 of 1 |
| 1M | +2.83% | +2.83% | 1 of 1 |
| 3M | +3.81% | +3.81% | 1 of 1 |
| YTD | +5.89% | +5.89% | 1 of 1 |
| INCEPTION | +13.09% | — | — |
Ranked among: Equity Oriented Investment Strategies - Sector Rotation Long-Short Fund.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +1.43% | +4.36% | -2.06% | 72% | 29% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity70.27%
- Debt6.39%
- Cash23.34%
- Other0.00%
Market Cap Split
- Large Cap32.00%
- Mid Cap30.62%
- Small Cap7.65%
- Others29.73%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 22.61 | 22.61 |
| P/B | 3.72 | 3.72 |
| Price / Sales | 3.59 | 3.59 |
| Price / Cash Flow | 13.89 | 13.89 |
| Dividend Yield (%) | 1.17 | 1.17 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| TREPS 01-Oct-2026 DEPO 10 | N.A. | 19.75% | — |
| Indus Towers | Telecom - Services | 9.33% | — |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 8.76% | — |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 7.18% | — |
| Bharti Airtel | Telecom - Services | 6.78% | — |
| Gujarat Themis Biosyn | Pharmaceuticals & Biotechnology | 5.81% | — |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 5.68% | — |
| Coal India | Consumable Fuels | 5.65% | — |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 5.61% | — |
| Lupin | Pharmaceuticals & Biotechnology | 5.28% | — |
| Biocon | Pharmaceuticals & Biotechnology | 4.89% | — |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 4.31% | — |
| NCA-NET CURRENT ASSETS | N.A. | 3.59% | — |
| Mphasis | IT - Software | 3.13% | — |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 2.95% | — |
View all 29 holdings
| Indegene | Equity | 1.84% | — |
| Coal India | Consumable Fuels | 1.84% | — |
| 91TB241226 | SOV | 1.59% | — |
| HCL Technologies | IT - Software | 1.19% | — |
| 91TB291026 | SOV | 0.80% | — |
| 91TB191126 | SOV | 0.80% | — |
| 91TB271126 | SOV | 0.80% | — |
| 91TB031226 | SOV | 0.80% | — |
| 91TB101226 | SOV | 0.80% | — |
| 91TB171226 | SOV | 0.80% | — |
| Biocon | Pharmaceuticals & Biotechnology | -4.82% | — |
| Lupin | Pharmaceuticals & Biotechnology | -5.18% | — |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | -5.68% | — |
| Bharti Airtel | Telecom - Services | -6.76% | — |
Sector Allocation · Sep 2026
Risk Metrics
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 3Y | 0.53 | 0.53 | Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
More From quant Money Managers Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
qsif Hybrid Long-Short Fund
Regular Plan · IDCW Option
|
+29.01% | — | — | +28.16% |
|
qsif Equity Long-Short Fund
Direct Plan · Growth Option
|
+11.08% | — | — | +11.66% |
|
qsif Active Asset Allocator Long-Short Fund
Regular Plan · Growth Option
|
— | — | — | +57.50% |
|
qsif Equity Ex-Top 100 Long-Short Fund
Regular Plan · IDCW Option
|
— | — | — | +13.53% |
About This Scheme
Investment Objective
To achieve long-term capital appreciation by concentrating investments in equity and equity-related instruments of up to four high-potential sectors, while employing limited short exposure through derivatives to capitalize on sector-specific downturns and enhance risk-adjusted returns.
Stated Asset Allocation
Investment in equity and equity-related instruments of maximum 4 sectors:- 80-100% Investment in debt and money market instruments:- 0-20% Investments in InVITS:- 0-20%
Exit Load
Exit Load: 3% if redeemed/switched out on or before completion of 30 days from the date of allotment of units No Exit Load is payable if Units are redeemed / switched-out after 30 days from the date of allotment
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.